What are the risks of maternal cannabis use at delivery and how should a mother who tests positive for cannabis and has an infant with hypoxic‑ischemic encephalopathy be managed?

Management of Maternal Cannabis Use with Concurrent Neonatal HIE

The mother's positive cannabis test at delivery is not the cause of the infant's hypoxic-ischemic encephalopathy (HIE), and management should focus on therapeutic hypothermia for the HIE while addressing the cannabis exposure separately through appropriate reporting, support services, and counseling about cessation.

Understanding the Clinical Scenario

The critical distinction here is that cannabis use does not cause HIE. HIE results from acute perinatal hypoxic-ischemic events during labor and delivery. While maternal cannabis use is associated with various adverse outcomes, acute intrapartum asphyxia leading to HIE is not among them.

What Cannabis Actually Causes

Based on the most recent meta-analysis, maternal cannabis use is associated with 1:

• Low birth weight (RR 1.69) and reduced birth weight by approximately 178 grams
• Small for gestational age (RR 1.79)
• Preterm delivery (RR 1.39) with gestational age reduced by approximately 0.21 weeks
• Major congenital anomalies (RR 1.81)
• Increased NICU admission (RR 1.55)
• Perinatal mortality (RR 1.72)
• Reduced head circumference, birth length

Additionally, longer-term neurodevelopmental concerns include increased risks of autism spectrum disorder, ADHD, psychosis proneness, attention problems, and executive function impairment 2.

Importantly, cannabis testing at birth does not predict immediate neonatal resuscitation needs, APGAR scores, or cord gases 3. This aligns with the clinical picture—cannabis doesn't cause the acute cardiorespiratory collapse that leads to HIE.

Immediate Management Algorithm

1. Prioritize HIE Treatment

Initiate therapeutic hypothermia immediately if the infant meets criteria (≥37 weeks gestation, moderate-to-severe HIE, within 6 hours of birth) 4. This is the evidence-based standard of care with proven mortality and morbidity benefits. The cannabis exposure does not contraindicate or modify hypothermia protocols.

The protocol should include 4:

• Target temperature 33-34°C
• Duration of 72 hours
• Controlled rewarming over at least 4 hours
• Comprehensive NICU support with respiratory support, antiseizure medications, and continuous monitoring

2. Assess Cannabis-Related Neonatal Effects

While cannabis didn't cause the HIE, evaluate for cannabis-specific concerns:

• Monitor for withdrawal symptoms: irritability, tremors, sleep disturbances (though these are uncommon in neonates)
• Assess growth parameters: document birth weight, length, head circumference as cannabis exposure may have contributed to growth restriction
• Screen for congenital anomalies: given the 1.81-fold increased risk 1

3. Address Breastfeeding Decisions

Counsel the mother to avoid cannabis use during breastfeeding 5, 6. The FDA and U.S. Surgeon General explicitly advise against cannabis use while breastfeeding 5. THC transfers into breast milk and case reports document potential neurologic effects including apneic episodes 7.

If the mother continues cannabis use:

• Recommend formula feeding as the safer alternative
• Document the counseling and her decision
• If she chooses to continue breastfeeding despite counseling, this requires close infant monitoring

4. Mandatory Reporting and Social Services

Positive maternal drug screens at delivery typically trigger mandatory reporting requirements (varies by jurisdiction):

• Contact social services/child protective services as required by local law
• Document the positive test, counseling provided, and follow-up plan
• Arrange substance use disorder evaluation and treatment resources
• Assess for other substance use, mental health needs (cannabis users often report using for depression/anxiety 7)

5. Counseling About Future Pregnancies

Strongly advise complete cannabis cessation for any future pregnancies 5, 6. Provide specific education about:

• The 1.69-fold increased risk of low birth weight
• The 1.79-fold increased risk of small for gestational age
• The 1.81-fold increased risk of major anomalies
• Neurodevelopmental risks in childhood including ADHD and ASD 2

Common Pitfalls to Avoid

1. Don't attribute the HIE to cannabis use: This misattributes causation and may delay appropriate HIE investigation (cord accidents, placental abruption, maternal hemorrhage, etc.)

2. Don't delay therapeutic hypothermia: The cannabis exposure is irrelevant to the decision to cool—focus on the HIE criteria and 6-hour window 4

3. Don't assume the infant will test positive: Only 51.3% of infants test positive when mothers test positive 3, and infant testing doesn't predict immediate clinical outcomes

4. Don't provide vague harm reduction advice: Be explicit that cannabis should be completely avoided during breastfeeding, not "reduced" or "minimized"

Evidence Strength Considerations

The recommendations against cannabis use during pregnancy and lactation are consistent across guidelines 5 and supported by robust meta-analytic evidence 1. However, the evidence linking cannabis to specific acute neonatal complications like HIE is absent—the associations are with growth, prematurity, and longer-term neurodevelopment, not acute perinatal asphyxia.

The therapeutic hypothermia recommendations for HIE are based on well-established RCT evidence and represent standard of care 4.